Publications

  • Increase font size
  • Decrease font size
  • Print
Normandin Beaudry

2013 articles

A new approach in underwriting high-cost drugs

In recent years, private drug plan sponsors have been faced with a serious issue: an increase in the number of covered individuals claiming very high-cost drugs for several years. The impact on private plans is significant and is even threatening their sustainability.

 

Click here to download the PDF file (PDF, 33 KB)
 

White Paper - A Solution for Private Drug Plans

In recent years, private drug plan sponsors have been faced with a serious issue: an increase in the number of covered individuals claiming very expensive drugs for several years. The impact on private plans is significant and is even threatening their sustainability.

 

This document aims to spark a discussion on the way in which high cost drugs reimbursed by private plans are underwritten by insurers, ensuring appropriate protection for sponsors and covered individuals. We propose an alternative that could be a lasting solution to the issue of high cost drug claims: underwriting the risk associated with high cost drugs in the same way as the risk associated with long-term disability benefits is underwritten.

 

Whether or not it is ultimately adopted by our industry, discussions will most definitely generate constructive ideas.
 

Le rapport D'Amours et ses enjeux

This article is available in French only.This article is available in French only.This article is available in French only.

 

Click here to download the PDF file (407 Kb).